PharmAla grants Jupiter Neurosciences exclusive U.S. rights to ALA-002
PharmAla Biotech Holdings has executed a definitive licence agreement with NASDAQ-listed Jupiter Neurosciences, granting Jupiter an exclusive, perpetual licence to develop, manufacture and commercialise ALA-002 in the United States. The deal was signed on 20 July 2026 and carries a headline value of up to approximately US$100 million.
ALA-002 is PharmAla's lead candidate: a patented, non-racemic MDMA formulation that holds New Chemical Entity designation from the FDA. The compound has been designed to offer an improved cardiovascular safety profile and reduced abuse liability compared with racemic MDMA, while preserving the therapeutic properties associated with MDMA-assisted psychotherapy. It remains investigational and has not been approved by any regulator.
Deal structure
The upfront consideration is US$3,333,333, split between US$1.5 million in cash and approximately US$1.83 million in Jupiter common stock, subject to a 120-day lock-up. Development and regulatory milestones could contribute a further US$23.3 million, including US$3.3 million on first patient dosing in a Phase 3 trial and US$20 million on FDA approval of a New Drug Application. Commercialisation milestones of up to US$73.3 million are tied to cumulative U.S. net sales thresholds of US$333 million, US$1 billion and US$2 billion. A 3% royalty on U.S. net sales applies after the third commercialisation milestone is reached.
PharmAla retains all rights to ALA-002 outside the United States and will supply GMP-grade drug product to Jupiter under a separate manufacturing agreement to be negotiated. The Toronto-listed company trades on the Canadian Securities Exchange under the ticker MDMA and on the OTCQB as MDXXF.
Nick Kadysh, founding chief executive of PharmAla, described the agreement as "a landmark transaction" that delivers near-term capital and a dedicated U.S. development partner while leaving international rights intact.
Market context
The deal lands at a sensitive moment for psychedelic-assisted therapies in the United States. In August 2024 the FDA declined to approve Lykos Therapeutics' NDA for MDMA-assisted therapy for post-traumatic stress disorder, citing concerns about trial design, functional unblinding and the adequacy of the safety database. That decision reset expectations across the sector and has prompted developers to refine their clinical and regulatory strategies ahead of any future submissions.
ALA-002's NCE designation is a meaningful differentiator in this environment: it confers five years of data exclusivity on approval and signals the FDA has accepted the formulation as a novel compound rather than a reformulation of an existing substance. Whether that protection, combined with revised trial design, is sufficient to address the agency's structural concerns about the MDMA modality remains the central regulatory question for the asset.
Jupiter adds ALA-002 to a pipeline that already includes JOTROL, a proprietary resveratrol formulation currently in a Phase 2a trial for Parkinson's disease, giving the company two clinical-stage programmes across neurodegeneration and neuropsychiatry. The psychedelic therapeutics space remains thinly capitalised relative to conventional CNS drug development, and the milestone-heavy structure of this deal reflects the commercial reality that upfront risk is difficult to price before Phase 3 data exists. Investors should note that the bulk of the potential US$100 million consideration is contingent on events that may not be achieved.